Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026
Biotech stock Alumis (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space.
Envudeucitinib is an oral therapy that works by selectively blocking TYK2, a kinase that plays a key role in immune system regulation. In late-stage trials, approximately 65% of patients treated for 24 weeks achieved a 90% reduction in plaque psoriasis symptoms, while more than 40% reached complete skin clearance. These results place envudeucitinib among the most effective oral therapies reported to date in this category.
The data suggest Alumis may be able to challenge treatments from Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX), whose drug icotrokinra targets IL-23, as well as Takeda Pharmaceutical’s (TAK) TYK2 inhibitor, zasocitinib. Leerink Partners analyst Thomas Smith said the results appear competitive with other late-stage oral psoriasis programs and could reduce risk across additional inflammatory indications where TYK2 plays a role.
Importantly, patients responded quickly. Clear separation from placebo was seen as early as week four, supporting the potential for class-leading efficacy. Alumis Chief Medical Officer Jorn Drappa described the data as demonstrating “the full promise of TYK2 inhibition.”
Safety also appeared favorable. Most side effects were mild to moderate and manageable with standard care, including headaches, colds, upper respiratory infections, and acne.
Alumis plans to submit its application to the Food and Drug Administration in the second half of 2026. With rivals set to present detailed data later this year, investors are now watching closely as envudeucitinib sets up what could be a defining competitive battle in psoriasis treatment.
You might like this article:Lithium’s Comeback: Why Albemarle Could Be Poised for a Strong 2026
